A detailed history of Fore Capital, LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Fore Capital, LLC holds 306,811 shares of PGEN stock, worth $230,108. This represents 0.14% of its overall portfolio holdings.

Number of Shares
306,811
Previous 206,811 48.35%
Holding current value
$230,108
Previous $326,000 10.74%
% of portfolio
0.14%
Previous 0.28%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.91 - $1.88 $91,000 - $188,000
100,000 Added 48.35%
306,811 $291,000
Q2 2024

Aug 07, 2024

SELL
$1.27 - $1.75 $126,974 - $174,965
-99,980 Reduced 32.59%
206,811 $326,000
Q1 2024

May 07, 2024

SELL
$1.21 - $1.75 $60,500 - $87,500
-50,000 Reduced 14.01%
306,791 $444,000
Q4 2023

Feb 13, 2024

SELL
$0.89 - $1.41 $62,300 - $98,700
-70,000 Reduced 16.4%
356,791 $478,000
Q3 2023

Nov 06, 2023

SELL
$1.08 - $1.85 $68,265 - $116,936
-63,209 Reduced 12.9%
426,791 $606,000
Q1 2023

May 09, 2023

BUY
$0.88 - $2.19 $338,800 - $843,150
385,000 Added 366.67%
490,000 $519,000
Q4 2022

Feb 13, 2023

SELL
$1.27 - $2.26 $114,300 - $203,399
-90,000 Reduced 46.15%
105,000 $159,000
Q3 2022

Nov 10, 2022

SELL
$1.41 - $2.79 $141,000 - $279,000
-100,000 Reduced 33.9%
195,000 $413,000
Q2 2022

Aug 08, 2022

BUY
$1.15 - $2.53 $184,000 - $404,799
160,000 Added 118.52%
295,000 $395,000
Q1 2022

May 11, 2022

BUY
$1.91 - $3.98 $257,850 - $537,300
135,000 New
135,000 $285,000
Q3 2021

Nov 12, 2021

SELL
$4.99 - $6.55 $49,900 - $65,500
-10,000 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$6.24 - $8.22 $62,400 - $82,200
10,000 New
10,000 $65,000
Q2 2020

Aug 13, 2020

SELL
$2.16 - $5.46 $60,588 - $153,153
-28,050 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.46 - $7.19 $40,953 - $201,679
28,050 New
28,050 $95,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $156M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Fore Capital, LLC Portfolio

Follow Fore Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fore Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fore Capital, LLC with notifications on news.